Annual Report 2024
Department of Pharmacy
Toshikatsu Kawasaki, Masahito Yonemura, Yasuaki Ryushima, Naoko Kumazawa, Daisuke Kano, Shinya Suzuki, Shinichi Masuda, Kenji Kawasumi, Chihiro Ishii, Akira Shinohara, Yoshihiro Iwamoto, Misaki Takeno, Azumi Sako, Ayumi Komuro, Kentaro Abe, Sayaka Nakajima, Akiko Hashimoto, Shinya Uozumi, Masaki Tanaka, Kanako Kusuhara, Takashi Igarashi, Hidetaka Suzuki, Ken Demachi, Asumi Kaneko, Kazuki Sugisaki, Maho Nakamura, Kaho Miura, Yuma Shibutani, Mashiro Okunaka, Manami Harada, Kenya Tanimoto, Atsushi Kawanobe, Kaede Baba, Takeyuki Fujiki, Wataru Yoshimura, Hiroki Sato, Shu kato, Momoka Furuoka
The Team and What We Do
The main objectives of the Department of Pharmacy are: (1) To promote clinical studies to create new evidence-based data; (2) To provide chemotherapy based on the most updated evidence-based data; and (3) To pursue patient-centered pharmaceutical care.
Our resident training program started in 2006. In 2024, seven residents joined our department. Presently, we have a total of 20 residents. In addition, our department accepted four trainees from other institutions for our oncology pharmacist training programs in 2024. In 2024, we educated three pharmacy students.
The Department of Pharmacy provides various important services: controlling inventory, dispensing medications, and preparing i.v. solutions for chemotherapy, which include the aseptic mixing of antineoplastic agents, collecting and providing drug information, managing therapeutic drug monitoring, checking treatment regimens for each patient's chemotherapy, and providing pharmaceutical management and counseling.
Our department reviews the drugs taken by patients before and during their hospitalization. For inpatient care, our department assigns pharmacists to provide medication counseling and drug information for healthcare providers and patients, to pursue effective pharmaceutical care. For outpatient care, our department provides a pharmacy outpatient service, in which pharmacists check patients for adverse reactions and doses of antineoplastic agents, particularly for oral anticancer medications. We assess the necessity of supportive care medications and coordinate with physicians. The pharmacy outpatient service also reviews the drugs taken by all patients to assess the optimal time for them to stop their anticoagulants before their surgery or stop taking metformin before examinations with iodinated contrast material. Pharmacists are on duty at the Outpatient Chemotherapy Center as dedicated staff members. The pharmacists provide a Chemotherapy Hotline Service, which is a direct line for our outpatients who have any problems concerning their chemotherapy treatment. In the Outpatient Chemotherapy Center, pharmacists are always available to provide drug information for healthcare providers and patients. We also provide treatment information to the patient's community pharmacy so that we can provide seamless pharmaceutical care. We also manage investigational drugs.
List of papers published in 2024
Journal
1. Shinohara A, Takumoto Y, Tauchi J, Morishita K, Kawasaki T, Akazawa M. Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data. Scientific reports, 15:267, 2025
2. Shibutani Y, Imaoka T, Suzuki A, Tajiri K. Withdrawal of Cardioprotective Therapy in Patients With Recovered Cancer Therapy-Related Cardiac Dysfunction. JACC. CardioOncology, 7:189, 2025
3. Kato S, Baba K, Mamishin K, Uematsu M, Shimura M, Hirota A, Fukuda M, Takahashi N, Nakao T, Nakajima H, Funasaka C, Kondoh C, Harano K, Naito Y, Matsubara N, Hosono A, Kawasaki T, Mukohara T. The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer. Cancer medicine, 14:e70804, 2025
4. Shimotsuura Y, Ishizuka K, Kawaguchi T, Umetsu K, Harada M, Inoue Y, Kubo E, Kosugi K, Igarashi T, Enomoto S, Taniyama H, Iwata T, Yamaguchi T, Matsumoto Y, Miura T. Effects of High-Resolution Natural Sound with Inaudible High-Frequency Components on Healing, Symptoms, and Sleep Satisfaction in Terminally Ill Cancer Patients. Palliative medicine reports, 6:53-60, 2025
5. Shibutani Y, Kawanobe A, Suzuki S, Imaoka T, Tajiri K. Effects of Immune Checkpoint Inhibitor-induced Thyroid Dysfunction on Cardiac Troponin Levels. Journal of immunotherapy (Hagerstown, Md. : 1997), 48:183-188, 2025
6. Matsumoto K, Ryushima Y, Sato J, Aizawa Y, Aoyama T, Akaishi Y, Okamoto R, Sato Y, Sugano K, Tazumi K, Tsuji M, Fujikawa N, Bun S, Yagasaki K. Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology. ESMO open, 9:103932, 2024